Blockchain in Healthcare: Patient Data, Drug Traceability, and Clinical Trials

The US Drug Supply Chain Security Act (DSCSA), which came into full enforcement in November 2023 after multiple deadline extensions, mandates electronic, interoperable drug traceability at the unit level across the pharmaceutical supply chain. The technical requirement for unique product identifiers, verified transaction history, and rapid saleable returns verification created a strong commercial incentive for blockchain-based pharmaceutical supply chain solutions that could satisfy the DSCSA requirements at scale. MediLedger, a blockchain network specifically built for pharmaceutical supply chain compliance, counts Pfizer, Genentech, AmerisourceBergen, and Cardinal Health among its members.

Healthcare’s relationship with blockchain is more nuanced than early enthusiasm suggested and more substantive than later dismissal implied. The technology is neither the universal healthcare data problem solver that its proponents claimed in 2017 and 2018, nor is it irrelevant, as the disillusionment cycle suggested by 2022. In 2026, blockchain in healthcare is characterised by specific deployed applications where its properties (immutability, decentralised verification, transparent audit trail) provide genuine value, alongside a larger territory of proposed applications that remain in proof-of-concept or have been abandoned.

Drug Traceability: The Most Mature Application

Pharmaceutical supply chain traceability is the healthcare blockchain application with the most mature deployment in 2026. The problem it addresses is significant: the World Health Organization estimates that approximately 10 percent of medicines in low- and middle-income countries are substandard or falsified, and drug counterfeiting in high-income countries, while lower in prevalence, produces documented patient harm events annually.

The DSCSA compliance requirement for unit-level product identifiers (the Drug Identifier or NDC, lot number, expiration date, and serial number encoded in a 2D DataMatrix barcode on each package) creates a data trail that blockchain can anchor immutably. MediLedger’s implementation uses a private blockchain (specifically Quorum, a permissioned Ethereum variant) that allows pharmaceutical manufacturers, distributors, and dispensers to verify product legitimacy and complete saleable returns verification without sharing proprietary business data between competitors.

The specific blockchain advantage in pharmaceutical traceability is the audit trail integrity: because the ledger is distributed across multiple parties and cryptographically sealed, no single party can alter historical transaction records without detection. A distributor cannot retroactively claim a return was verified if it was not; a manufacturer cannot deny a shipment was made if it appears in the ledger. This property directly addresses the verification fraud that drug counterfeiting operations exploit in supply chains with centralised, alterable records.

Patient Data and Health Record Interoperability

Health record interoperability is the blockchain healthcare application that has generated the most research attention and the most sceptical critique simultaneously. The core problem is genuine: patient health records are fragmented across multiple healthcare providers (primary care, specialists, hospitals, pharmacies, lab companies) who use different Electronic Health Record (EHR) systems with limited interoperability. When a patient sees a new provider, their prior records often arrive late, incompletely, or not at all, producing repeated tests, prescribing errors from incomplete medication history, and suboptimal care decisions.

Blockchain’s theorised role in health record interoperability is as a patient-controlled access management layer: rather than storing health records on the blockchain (which is technically impractical given the data volumes and privacy requirements), a blockchain ledger stores the access permissions and audit trails for who has accessed health records stored in conventional healthcare data systems. The patient holds a private key that grants and revokes access permissions, creating genuine patient control over their health data.

The practical implementations of this model in 2026 are limited and mostly in pilot or limited deployment stages. Medibloc in South Korea, Iryo in the EU, and Solve.Care’s care coordination platform have deployed versions of this model in specific regional contexts. The barriers are not primarily technological: they are the governance complexity of healthcare data exchange across multiple jurisdictions with different privacy laws, the integration challenges with existing EHR systems that were not designed for blockchain interfaces, and the patient usability challenge of managing cryptographic keys in a health emergency context.

Clinical Trials: Data Integrity and Transparency

Clinical trial data integrity is a blockchain application where the immutability property addresses a well-documented real-world problem. Clinical trial fraud and selective reporting of results are documented phenomena with significant patient safety consequences. The Vioxx scandal (where Merck was found to have not disclosed adverse cardiac events in trial data) and multiple subsequent cases of selective outcome reporting demonstrated that centralised, mutable trial data creates opportunities for post-hoc manipulation.

Blockchain’s role in clinical trials is anchoring trial data at the point of collection to an immutable record that makes retroactive manipulation detectable. If a trial’s primary outcome measures are registered on a blockchain at the protocol registration stage, and data collection events are anchored at the point of recording, any subsequent alteration of the data or outcome definitions would be detectable against the original blockchain record.

Triall, a Netherlands-based company, has deployed blockchain-based clinical trial document management with pharmaceutical clients. The FDA’s Centre for Drug Evaluation and Research issued a discussion paper in 2023 on blockchain use cases in clinical trials that acknowledged the integrity property while raising questions about scalability and integration with existing clinical data management systems.

Mental Models for What Blockchain Solves in Healthcare

The most useful framework for evaluating healthcare blockchain applications is asking: does the specific problem require a trusted, shared, immutable record that multiple parties contribute to and verify, without a central authority that all parties trust? If yes, blockchain has a genuine advantage. If the problem can be solved by a centralised, well-audited database with appropriate access controls, blockchain adds cost and complexity without proportional benefit.

Drug traceability passes this test because multiple competing companies (manufacturers, distributors, dispensers) need to share verification data without trusting each other’s individually maintained records. Patient data interoperability is more ambiguous because centralised health information exchanges (HIEs) can solve much of the same problem with better-understood technology if governance challenges are addressed. Clinical trial integrity passes the test where the specific concern is manipulation by the trial sponsor, which a centralised database maintained by the sponsor does not prevent.